Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 8/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24829030 | 0.92 | P2RY6 (0.42) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL24829020 | 0.91 | POLB (0.40) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL24828895 | 0.90 | LMNA (0.43) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL24829018 | 0.90 | POLB (0.40) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL24829027 | 0.90 | POLB (0.40) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL24829028 | 0.88 | POLB (0.39) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL24828949 | 0.88 | P2RY6 (0.40) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL24829444 | 0.88 | P2RY6 (0.40) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL24829226 | 0.88 | P2RY6 (0.40) | POLBLMNATHRBMTORMDM2 | |
| SCHEMBL24829224 | 0.88 | POLB (0.39) | POLBLMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11541071-B1 | Nucleoside derivatives and methods of use thereof | Ascletis BioScience Co., Ltd (CN) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190782-A1 | NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF | TYMP, NUDT1, PNP | POLB 63/4885LMNA 463/4885THRB 4221/4885 |
| US-11541071-B1 | Nucleoside derivatives and methods of use thereof | TYMP, NUDT1, PNP | POLB 63/4885LMNA 463/4885THRB 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.